In order to evaluate the therapeutic effect of OCA on the progression of NASH, MC4R-KO mice were fed WD for 20 weeks and then received OCA (10 mg/kg) or its vehicle for 4 or 8 weeks (Fig. 6a). Here, MC4R is linked to metabolic dysfunction-associated steatohepatitis.